Related Experiment Video
Updated: Sep 9, 2025

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Quantifying lifetime risk for 1,401 infectious diseases across the diabetes spectrum using a Bayesian approach
Boomer B Olsen1, Martin Tristani-Firouzi2, Karen Eilbeck3
1Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
None:
Although many diabetes complications have been extensively studied, less is known about the burden of infectious diseases. We developed a Bayesian approach to compare infection risk across 9,476 patients with type 1 diabetes (T1D), 74,270 with type 2 diabetes (T2D), and 32,095 with prediabetes. Patients with T1D, T2D, and prediabetes had multifold increased risk for all organ system- and pathogen-based composite infection outcomes. We also quantified risk for 1,401 individual infection outcomes, finding increased risk for 880 in T1D, 1,047 in T2D, and 991 in prediabetes. Patients had increased risk for well-established diabetes-associated infections (e.g., mucormycosis) and less commonly associated infections (e.g., West Nile Virus encephalitis). Finally, we found disparities in risk across sociodemographic subgroups (i.e., age, sex, ethnicity, ancestry, and insurance status). Our comprehensive findings advance previous research by quantifying risk for wide-ranging infection outcomes across diverse patients with T1D, T2D, and prediabetes through an innovative Bayesian approach.
Related Concept Videos
Kaplan-Meier Approach
Relative Risk
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Statistical Methods for Analyzing Epidemiological Data
Probability Laws
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

